Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...

TOS-358 is an oral, highly selective, pan-mutant, covalent PI3Ka inhibitor that achieves >95% continuous target engagement for deep and durable inhibition of PI3K-AKT signaling which is required for ...

The FDA clears 1st oral pill for plaque psoriasis, approving Johnson & Johnson’s Icotyde for adults and pediatric patients age 12 and older.

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 years and older.

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Pfizer said on Tuesday its experimental combination reduced the ​risk of disease progression or death by 40% in patients with breast cancer.

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, ...

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.

Evidence shows that birth control pills containing the hormones estrogen and progestin can increase the risk of different types of cancers and decrease the risk of others.  Since 1999, the World ...